Table 3.
Baseline predictors of final visual outcome after 12 months after the first DEX injection.
| Baseline measure | CDVA loss >1 line n (%) | CDVA gain or loss ≤1 line n (%) | CDVA gain >1 line n (%) | p value | OR (95% CI)∗ |
|---|---|---|---|---|---|
| Baseline CDVA (log MAR ± SD)† | 0.47 ± 0.34 | 0.50 ± 0.26 | 0.70 ± 0.30 | 0.001 | 1.485 (1.171–1.884) |
|
| |||||
| Indication for surgery | 0.046 | 1.168 (1.003–1.360) | |||
| ERM | 5/46 (11) | 6/46 (13) | 35/46 (76) | ||
| RRD | 4/15 (27) | 4/15 (27) | 7/15 (46) | ||
|
| |||||
| Lens status | 0.820 | 1.015 (0.890–1.159) | |||
| Phakic | 3/27 (11) | 5/27 (19) | 19/27 (70) | ||
| Pseudophakic | 6/34 (18) | 5/34 (15) | 23/34 (67) | ||
|
| |||||
| Naïve status | 0.853 | 0.946 (0.871–1.137) | |||
| Naïve | 2/18 (11) | 2/18 (11) | 14/18 (78) | ||
| Previously treated | 7/43 (16) | 8/43 (19) | 28/43 (65) | ||
|
| |||||
| IRF/cysts | 0.465 | 1.055 (0.915–1.216) | |||
| Absence of IRF/cysts | 1/8 (12) | 2/8 (25) | 5/8 (63) | ||
| Presence of IRF/cysts | 7/53 (13) | 8/53 (15) | 38/53 (72) | ||
|
| |||||
| SRF | 0.043 | 0.860 (0.743–0.995) | |||
| Absence of SRF | 8/43 (19) | 9/43 (21) | 26/43 (60) | ||
| Presence of SRF | 0/18 (0) | 1/18 (6) | 17/18 (94) | ||
|
| |||||
| EZ continuity | 0.209 | 1.094 (0.951–1.257) | |||
| Completely continuous | 4/12 (33) | 2/12 (17) | 6/12 (50) | ||
| Partially disrupted | 3/31 (10) | 3/31 (10) | 25/31 (80) | ||
| Completely disrupted | 1/18 (6) | 5/18 (28) | 12/18 (66) | ||
|
| |||||
| Onset of PCME to surgery | 0.827 | 0.985 (0.871–1.137) | |||
| <3 months | 7/38 (18) | 3/38 (8) | 28/38 (74) | ||
| >3 months | 2/23 (9) | 7/23 (30) | 14/23 (61) | ||
|
| |||||
| Time between surgery and first DEX | 0.982 | 0.999 (0.901–1.107) | |||
| <6 months | 6/36 (17) | 7/36 (19) | 23/36 (64) | ||
| >6 months | 3/25 (12) | 3/25 (12) | 19/25 (76) | ||
CDVA: corrected distance visual acuity; CI: confidence interval; ERM: epiretinal membrane; RRD: rhegmatogenous retinal detachment; IRF: intraretinal fluid; SRF: subretinal fluid; EZ: ellipsoid zone; PCME: postoperative cystoid macular edema; DEX: dexamethasone intravitreal implant. ∗Odds ratio (OR) for a patient presenting with a gain of CDVA >1 line at 12 months when baseline measure is increased by 1 value. †For every less line (+0.1 log MAR) of baseline BCVA, a patient was more likely to gain >1 line in CDVA at 12 months after initial DEX injection.